Clinical trial · Observational
Study of the Immune Response in Colon Adenocarcinoma
Etude de la réponse Immunitaire Dans l'adénocarcinome Colique
NCT03015038CI-TRIAL-00098713IMCOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Duration of each part of the study per patient: * Screening: From 1 to 4 weeks * Sampling period (blood and tissue): 1 day * Follow-up by patient: 60 months * Total study duration by patient: 84 months * Total inclusion duration: 24 months * Total Follow-up duration: 60 months * Total study duration: 84 months
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Adenocarcinoma | Colon Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Immune cells trafficking
- timeFrame
- Day 0
- description
- Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab).
Secondary outcomes (2)
- measure
- Infiltration of leucocytes in tumor tissue
- timeFrame
- Day 0
- description
- Histochemical method with a panel of Ab.
- measure
- Safety (Number of adverse events, ECOG status)
- timeFrame
- After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged 18 or more. 2. Affiliation to a social security scheme 3. Diagnosis of a colon adenocarcinoma. 4. Patient have signed and dated consent of the study before undertaking procedures related to the study. Exclusion Criteria: 1. Patients under guardianship / curatorship 2. Following Situations * Persons unable to understand, read and / or sign an informed consent * Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study * Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year. * No affiliation to a social security scheme, a universal medical coverage or any similar plan. 3. Pregnant or lactating women. 4. Patients with HIV seropositivity. 5. Rectal tumor location.
References
Publications (2)
- RESULTBonnereau J, Courau T, Asesio N, Salfati D, Bouhidel F, Corte H, Hamoudi S, Hammoudi N, Lavole J, Vivier-Chicoteau J, Chardiny V, Maggiori L, Blery M, Remark R, Bonnafous C, Cattan P, Toubert A, Bhat P, Allez M, Aparicio T, Le Bourhis L. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. Gut. 2023 Apr;72(4):699-709. doi: 10.1136/gutjnl-2021-326553. Epub 2022 Jul 8. PMID 35803702
- RESULTCourau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A, Blery M, Aparicio T, Allez M, Le Bourhis L. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer. 2019 Mar 14;7(1):74. doi: 10.1186/s40425-019-0553-9. PMID 30871626